The fall of 23andMe raises privacy concerns as Regeneron buys its genetic database for $256M after bankruptcy.

Regeneron Pharmaceuticals is acquiring the assets of 23andMe for $256 million, excluding its Lemonaid Health business, as the company faces layoffs and office closure due to financial struggles and a past cyberattack.

Me, the embattled Bay Area genetic testing company, permanently closed its San Francisco office and warned 250 employees of possible layoffs as part of ongoing restructuring efforts following its Chapter 11 bankruptcy filing this year.

Genetic testing firm 23andMe must pay customers after personal information was exposed in a cybersecurity incident, if they submit claims by July 14.

Hey New Jerseyands, claims are now open for 23andMe's settlement over a data breach — and payouts may be as high as $10,000. Here's what to know.

The personal genomics company 23andMe filed for bankruptcy in March and agreed to pay $30 million to affected customers.

Back in November, the company cut about 200 jobs as part of what it called a “business restructuring to streamline operations.” KRON4.com has reached out to 23andMe more information.